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The purpose of this study was to identify risk factors for
the progression of low-grade glioma in children from a
large population-based cohort. Patient and tumor
details of a national cohort of children with low-grade
glioma, recruited into an international multidisciplinary
clinical strategy, were subjected to univariate and multi-
variate analyses of progression-free survival and overall
survival. From the cohort of 798 patients, 639 patients
were eligible, with a median age 6.71 years (0.26–
16.75 years); 49% were males; 15.9% had neurofibro-
matosis type 1, 63.7% pilocytic astrocytoma, 5.9%
fibrillary astrocytoma, 4.2% mixed neuronal-glial
tumors, and 3.6% others; 21.1% were diagnosed clini-
cally. Anatomically implicated were 31.6% cerebellum,
24.6% chiasma/hypothalamus, 16.0% cerebral hemi-
spheres, 9.9% brain stem, 6.1% other supratentorial
midline structures, 5.9% optic nerve only, 4.5% spinal
cord, and 1.4% others. The 5-year overall survival and
progression-free survival in the whole cohort were
94.6% and 69.4%, respectively. There was a significant
association between age and site (P < .001) and extent of
tumor resection and site (P < .001). Multivariate
analysis identified young age, fibrillary astrocytoma,
and extent of surgical resection as significant indepen-
dent risk factors for progression. Hypothalamic/chias-
matic tumors demonstrated the most sustained
tendency to progress. In conclusion, the influence of
age and anatomical site upon the risk of tumor pro-
gression suggests that these factors strongly influence
tumor behavior for the majority of pilocytic tumors.
Age <1 year and 1–5 years, fibrillary histology, comple-
teness of resection, and chiasmatic location are candi-
dates for stratification in future studies.
Keywords: children, low-grade astrocytoma, low-grade
glioma, multivariate, prognostic factors.
L
ow-grade gliomas (LGGs) constitute 40% of
central nervous system (CNS) tumors in chil-
dren.1 They are heterogeneous both anatomi-
cally and clinically. Histologically, they are separated
by World Health Organization (WHO) classification
into grades I and II.2 Pilocytic astrocytomas (PAs;
WHO grade I) are most common in children, whereas
diffuse fibrillary astrocytomas (FAs; WHO grade 2) are
less common than in adults. LGGs are associated with
neurofibromatosis type 1 (NF1)3 and can arise through-
out the brain and the spinal cord. Tumors may occasion-
ally present with leptomeningeal metastases, whereas
large and progressive tumors can threaten life, despite
treatment. Surgical resection, where possible, is the
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preferred treatment. However, certain anatomical sites
are unsuitable for complete resection. Nonsurgical treat-
ments with radiotherapy and, more recently, chemother-
apy are in trial. Incompletely resected or unresected
tumors may progress, remain stable, or even spon-
taneously involute.4,5
Focus on childhood benign astrocytomas is justified
by the coincidence of the early age distribution and the
brain’s state of growth and development at the time of
onset, determining the ages at which certain treatment
options, particularly radiotherapy, can be considered.
Despite the high frequency of LGG in children, no con-
sensus exists for identifying children at a sustained risk
for tumor progression. There have been no population-
based cohort studies of prognostic factors published
previously; those published are either retrospective,
institution-based,6–13 or multi-institutional clinical trials
selecting patients for chemotherapy.14–19 Most studies
deal with optic pathway gliomas (OPGs)6,9,11,12,18,19 or
gliomas of other specific locations,7,10 whereas studies of
prognostic factors at all sites are fewer.8,13–17 Most
studies are small, with only 3 including more than 100
patients.8,13,19Children are reported to have a better prog-
nosis than adults.20–22 However, within childhood,
studies on the prognostic value of age as a risk factor are
inconclusive. This may be due to the variable selection
of patients at different institutions, the small size of
many studies, specific eligibility criteria related to
inclusion in clinical trials, specific anatomical location(s)
recruited for study, different age limits for risk evaluation,
and variable endpoint: progression-free survival (PFS) or
overall survival (OS).
Identification of prognostic factors in childhood LGG
will be important for tailoring treatment in future clini-
cal studies. To address this, this study was done on the
LGG patient cohort of the Children’s Cancer and
Leukaemia Group’s (CCLG, formerly UKCCSG) study
CNS9702. This population-based cohort was used to
test the following hypothesis: “The risk of tumor pro-
gression in LGG in children is determined by age, sex,
NF1 status, anatomical site, histopathology and extent
of tumor resection.”
Patients and Methods
Patients
The CCLG (formerly UKCCSG) opened CNS9702 first
as a pilot study and then formally in February 1997.
The study was closed in April 2004. All patients less
than 16 years of age with LGG (WHO grades I and
II), including mixed neuronal-glial tumors, were eligible
through the CCLG network of 22 treatment centers.
This network registered 80%–86% of the UK cases of
childhood LGG registered by the national childhood
cancer registry during this time period. Patients with
tumors at all anatomical sites were recruited until
2002, when cerebellar tumor registration was discontin-
ued after an interim surgical review prior to this study’s
hypothesis development. Patients with MR findings and
clinical features typical of LGG, mostly NF1 patients
with classical OPG, could be included in the study
without biopsy. Clinical report forms were reviewed to
confirm the dates of diagnosis/birth, gender, and NF
status. Completed were the central reviews of histo-
pathology, anatomical site, timing and extent of tumor
resection, timing and choice of nonsurgical treatment,
dates of tumor progression, death, and last follow-up.
Treatment strategy
CNS9702 was part of an LGG study by the International
Consortium of Low-Grade Glioma (ICLGG) with an
integrated multidisciplinary strategy for all patients
(Fig. 1). Primary surgical resection or biopsy was rec-
ommended for all, except in patients with typical chias-
matic tumors and in NF1 patients, where a clinical
diagnosis was acceptable. Subsequently, further obser-
vation or nonsurgical therapy was determined by
imaging evidence of progression or by the presence of
severe symptoms or threat to vision. Chemotherapy
was recommended for patients aged ,5 years with vin-
cristine (1.5 mg/m2 once a week for 10 weeks, thereafter
every fourth week for 10 cycles) and carboplatin
(550 mg/m2 every third week for 4 cycles, thereafter
every fourth week for 10 cycles). Radiotherapy was rec-
ommended for patients aged .5 years. Focal radiother-
apy employed a margin of 1–2 cm around the gross
tumor volume. The radiation dose was 54 Gy for chil-
dren with intracranial tumors and aged .5 years and
50 Gy for spinal cord tumors and children aged ,5
years with intracranial tumors. For patients who sub-
sequently progressed on imaging or symptomatically,
reconsideration of surgical resection and subsequent
age-stratified, nonsurgical therapy was recommended.
There was good compliance with age stratification for
radiotherapy and chemotherapy (Fig. 1).
Methods
The central histopathology review blind to other clinical
details was conducted by J.W.I. and D.W.E. The
pathology review of sections from the registered cases
included an assessment of tumor histopathology on
hematoxylin and eosin–stained sections, with immuno-
histochemistry performed as required for diagnosis and
subclassification. The WHO classification for grade I
and II gliomas and mixed neuronal-glial tumors was
used2 (Table 1). Ependymomas were ineligible. The
anatomical review of imaging reports (T.S. and
D.A.W.) was performed blind to clinical details
(Table 1). Isolated optic nerve tumors were classified
separately from optic pathway tumors involving the
chiasm. Tumors spanning multiple areas and metastatic
tumors were allocated according to the predominant
primary component of tumor.
Extent of surgical resection was based on the local
reports. The definition followed the recommendation
of the Brain Tumour Subcommittee of the Socie´te´
Internationale d’Oncologie Pe´diatrique23 using both
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surgical and radiological judgments: total resection¼
both neurosurgeon and neuroradiologist’s judgments
agree that there is no residue (S1, R1); near total
resection¼small residue that may be invading, with or
without radiological enhancement (S2, R1–2); partial
resection¼measurable residual tumor of any size, and
the surgical assessment may or may not agree (S1–3,
R3); biopsy¼both surgical and radiological findings
agree that there has been no change postoperatively
(S4, R4). Tumor progression was defined by the local
reports of imaging and/or symptomatic progression.
Institutions obtained approval as required by their
local district research ethics committees. Informed
consent was obtained from all patients and/or their
legal guardian.
Statistical methods
Survival curves were calculated using the Kaplan–Meier
method. Time-to-event endpoint was defined as death
from all causes for OS or first progression for PFS.
Deaths as a first event without evidence of glioma recur-
rence (n ¼ 4) were censored in PFS analysis. The differ-
ence in survival distributions were tested by the
log-rank test. For multivariate analysis, Cox’s pro-
portional hazards regression model was used to estimate
hazard ratios (HRs) and 95% confidence intervals (CIs).
Predictors included in the adjusted model were age at
diagnosis (,1, 1–3, 3–5, 5–10, and .10 years),
gender, NF1 status, pathology, anatomical site, treat-
ment decision after diagnosis and surgery (observation,
chemotherapy, and radiotherapy), and the extent of
tumor resection and metastasis within the CNS. All vari-
ables were fitted as dummies. The significance level for
all analyses was set at 5%. Statistical analyses were per-
formed with Statistical Package for Social Services, 14.0
(SPSS Inc., Chicago, IL) or STATA 9.0 (Stata Corp.,
College Station, TX).
Results
Recruitment and strategy
Of 798 registered patients, 159 were excluded, most due
to missing material for the central pathology review or
change in histological diagnosis, 20 patients being
regraded as high-grade glioma, leaving 639 for analysis.
Four hundred and seventy-four (74.2%) were initially
observed (median age: 7.43 years; Fig. 1). One
hundred and sixty-five (25.8%) started nonsurgical
treatment (median age: 4.95 years), 113 had chemother-
apy (median age: 3.65 years), and 52 had radiotherapy
(median age: 9.36 years).
Clinicopathological characteristics
The median age of the whole cohort was 6.71 years
(range: 0.26–16.75). The age distribution was bimodal
with peaks at 4 and 13 years (Fig. 2A). Sex distribution
was equal with 313 males (49.0%). NF1 was reported in
101 patients (15.9%), no patients with NF2 were
recorded.
Fig. 1. Study population and treatment strategy.
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Table 1. Pathology, site, and metastasis
Eligible for analysis (n5 639)
n Percenta
Pathology
Pilocytic astrocytoma 407 63.7
Pilomyxoid astrocytoma 9 1.4
Fibrillary astrocytomab 38 5.9
Other astrocytomasc 23 3.6
Astrocytoma NOSd 11 1.7
Subependymal giant cell astrocytoma 6 0.9
Pleomorphic xanthoastrocytoma 3 0.5
Cerebral astrocytoma with extensive calcificatione 3 0.5
Mixed neuronal-glial tumors 27 4.2
Ganglioglioma 14 2.2
Dysembryoplastic neuroepithelial tumor (DNET) 11 1.7
Desmoplastic infantile astrocytoma/ganglioglioma (DIA/DIG) 2 0.3
Clinical diagnosis (no biopsy performed) 135 21.1
Site
Cerebral hemisphere 102 16.0
Frontal 18 2.8
Parietal 17 2.7
Temporal 38 5.9
Occipital 11 1.7
Ventricles lateral and third ventricle 18 2.8
Optic nerve only 38 5.9
Chiasma/hypothalamus 157 24.6
Other supratentorial midline 39 6.1
Thalamus 29 4.5
Basal ganglia 6 0.9
Pineal gland 4 0.6
Cerebellumf 202 31.6
Brain stem 63 9.9
Midbrain 16 2.5
Pons 19 3.0
Medulla oblongata 13 2.0
Cervicomedullary 6 0.9
Fourth ventricle 9 1.4
Spinal 29 4.5
Cervical 8 1.3
Thoracal 20 3.1
Conus 1 0.2
Othersg 9 1.4
Metastasis within CNS
No 583 96.4
Yes 22 3.6
Abbreviations: CNS, central nervous system; NOS, not otherwise specified.
aOf all biopsied tumors (n ¼ 504): pilocytic astrocytoma 80.8%, pilomyxoid astrocytoma 1.8%, fibrillary astrocytoma 7.5%, other
astrocytomas 4.5%, and mixed neuronal-glial tumors 5.4%.
bAll diffuse grade II astrocytoma were fibrillary, no gemistocytic, or protoplasmic astrocytoma.
cThere were no oligodendrogliomas diagnosed.
dNot possible to ascertain whether pilocytic or diffuse astrocytoma due to limited size of biopsy.
eProvisional classification of this entity pending further investigations.
fCerebellum tumors not recruited in the last part of the study period (36.1% of all in the recruitment period).
gMultiple site (n ¼ 5) and difficult to decide (n ¼ 4).
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The results of histopathology review are shown in
Table 1. PA (63.7%) predominated, followed by diffuse
FA (5.9%),mixed neuronal-glial tumors (4.2%), pilomyx-
oid astrocytoma (PMA; 1.4%). A group of miscellaneous
entities included subependymal giant cell astrocytomas,
which were all ventricular (n ¼ 6), and pleomorphic
xanthoastrocytomas (n ¼ 3), unclassifiable astrocytomas
(n ¼ 11), and 3 unusual cerebral astrocytomaswith exten-
sive dystrophic calcification, which had neither typical
diffuse nor pilocytic features. There were no oligodendro-
gliomas or gemistocytic or protoplasmic variants of diffuse
astrocytoma. A clinical diagnosis was accepted in 135
(21.1%), including 8 patients who had noninformative
biopsy and 1 patient recruited based on typical imaging
before surgery whose tumor material was not available
for central review; 90 (87.4%) were associated with NF1.
The relative frequency of tumors at anatomical sites is
shown (Table 1). Recruitment of cerebellar cases was
discontinued in 2002; the proportion of cerebellar
cases during the period 1994–2001 was 36.1% com-
pared with an overall proportion of 31.6%. Brain stem
tumors were heterogeneously distributed (e.g. tectum/
midbrain vs pons), and spinal tumors were mostly thor-
acic. Metastatic spread at the time of diagnosis was
recorded in 22 out of the 639 patients; 34 patients had
missing data.
Fig. 2. Age and site distribution. (A) Age distribution, all; (B) age distribution, chiasma/hypothalamus; (C) age distribution, cerebral hemisphere;
(D) age distribution, cerebellum; (E) median age by site; (F) extent of tumor resection by site.
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Total surgical resection was recorded in 205 patients
(32.3%), near total resection in 105 (16.6%), partial
resection in 87 (13.7%), biopsy only in 103 (16.2%),
and no surgery in 134 (21.1%); 5 patients had no surgi-
cal resection data.
Correlation between variables
Age-incidence distributions differed significantly (P,
.001) among anatomical sites: chiasmatic/hypothalamic
tumors had a skewed distribution toward younger age,
hemispheric tumors had a skewed incidence toward the
older age groups, cerebellar tumors had a bimodal age
distribution with peaks at 7 and 13 years, none occurring
below 1 year (Fig. 2B–F). Patients less than 1 year had
predominantly supratentorial midline tumors, 19 of the
28 being at the chiasma/hypothalamus. There was no
significant difference in age distribution between FA
and PA (median 8.89 vs 7.35, P ¼ .705); median age of
clinical diagnosis patients was younger, at 5.06 years.
PA predominated at all sites, whereas FA was infrequent
in the cerebellum and the optic pathway (1.5% and
0.4%), occurring at a frequency of 11%–17% at other
sites (P, .001). The association between NF1 and
optic pathway tumors was more marked in isolated
optic nerve (70%) than chiasmatic/hypothalamic
(37.5%) tumors. Surgical resectability of tumors was
dependent on the tumor site (P, .001); cerebellar
tumors were resected in 94.0% of patients, whereas in
chiasmatic/hypothalamic tumors, only 3.2% were sub-
totally or completely resected (Fig. 2F).
Univariate analysis of survival
After a median follow-up (time to last follow-up or
death) of 4.26 years (0.01–10.15), 3- and 5-year PFS
for the whole cohort was 73.0% and 69.4% (Fig. 3A),
respectively, and 3- and 5-year OS was 96.68% and
94.62% (Table 2, Fig. 4A). Histopathology predicted
for PFS, with PA and FA having 5-year PFS of 71.5%
and 42.6%, respectively (P, .001; Fig. 3B). Clinically
diagnosed cases had similar PFS to PA. Minor histo-
pathological subgroups were too small to analyze,
although only 5 of 9 PMAs were alive after a short
observation time.
Age predicted for PFS, with ,1, 1–3, 3–5, 5–10,
and .10 years having 5-year PFS of 41%, 56%, 58%,
79%, and 77.2%, respectively (P, .001; Fig. 3C).
This pattern was most prominent in tumors of
chiasma/hypothalamus but also at other sites
(Fig. 3D). There was nearly identical PFS in the age
groups 1–3 and 3–5 years, and likewise in 5–10 and
.10 years. In contrast to PFS, OS did not differ
between the 1–5- and .5-year age groups (Fig. 4B).
There was no difference in PFS for NF1 status for the
whole cohort (Fig. 3E), although NF1+ patients with
chiasmatic/hypothalamic tumors had significantly
better PFS than those without NF1, with 5-year PFS
70.8% vs 46.7%, respectively (P, .001; Fig. 3F).
Tumor location was associated with different patterns
in PFS, with isolated optic nerve tumors and cerebellar
tumors having 5-year PFS of 85%–86% and a survival
curve plateau; supratentorial midline sites had a survival
plateau curve with 5-year PFS of 49%–50%, whereas
chiasmatic/hypothalamic tumors had 5-year PFS of
50.2% with a survival curve with no plateau (Fig. 3G).
Total resection predicted for 5-year PFS of 94% vs
48.6% for partial resection (P, .001; Fig. 3H). There
was no gender difference.
Multivariate analysis
Age, histology, and extent of resection were independent
risk factors for progression. Younger age groups (,1,
1–3, and 3–5 years) in general showed poorer
outcome, but only ages 3–5 years reached significance
in the multivariate model (adjusted HR: 1.87, 95% CI:
1.14–3.09; Table 2). On the basis of the similar PFS
pattern observed in younger age groups, we have also
tried fitting age as 4 groups (,1, 1–5, 5–10, and .10
years) in the multivariate model. Age group 1–5 years
showed a significant increased risk for progression
(adjusted HR: 1.74, 95% CI: 1.11–2.73). FA was an
independent predictor of progression (adjusted HR:
1.99, 95% CI: 1.11–3.58).
Compared with total resection, there was an
increased risk for progression observed in near total
resection (adjusted HR: 8.19, 95% CI: 3.97–16.91),
partial resection (adjusted HR: 12.27, 95% CI: 5.58–
26.99), biopsy (adjusted HR: 11.38, 95% CI: 4.99–
25.97), and no surgery (adjusted HR: 19.79, 95% CI:
6.11–64.14) based on the entire population.
Tumors in cerebral hemisphere(s), chiasma/hypo-
thalamus, other supratentorial midline, brain stem, and
spinal all showed a greater risk for progression than
tumors at the cerebellum in univariate analysis.
However, apart from chiasma/hypothalamus, which
showed a borderline significance (adjusted HR: 1.74,
95% CI: 0.92–3.31), none remained significant after
adjusting for other variables.
Forward and backward stepwise regression was used
to explore predictors for progression. Variables in the
best fitted model are age, pathology, and tumor resec-
tion, and HRs were similar to those derived from full
models (data not shown).
Discussion
This population-based cohort, recruited over a 7-year
period with a median follow-up time of 4.7 years, has
permitted multivariate modeling of patient, tumor, and
treatment variables predictive of tumor progression in
a large series of LGGs. Such an analysis in such a large
population-based cohort has not been published pre-
viously. The study complies with validity criteria rec-
ommended for systematic reviews24,25 used in the only
published systematic review of prognostic factors of
LGG in children, studying optic pathway tumors.26
The current study is focused upon a well-defined popu-
lation, representing 80%–86% of the UK registrations.
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Fig. 3. The Kaplan–Meier curves of PFS. (A) PFS, all; (B) by pathology; (C) by age; (D) by age at nonoptic pathway glioma (non-OPG) sites;
(E) by NF1 status; (F) by NF1 status at chiasma/hypothalamus; (G) by site; (H) by extent of tumor resection.
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All patients eligible and entered into the study were fol-
lowed up. In this study, referral bias cannot be entirely
excluded. However, the proportion of UK childhood
cancer registrations exceeds the 70% response rate nor-
mally taken as indicative of a representative sample. The
sex and NF1 parameters of this cohort are comparable
to other reports.8,13
The multidisciplinary strategy with predetermined
clinical and imaging evidence of progression was used
to justify clinical re-evaluation and the option for
further therapy. The central anatomical and pathologi-
cal reviews were performed blind to clinical details.
The selection of PFS rather than OS as the primary end-
point provides more events for analysis and reduces the
Table 2. Five-year overall survival, progression-free survival, and hazard ratios
Total Overall survival Progression-free survival
Events 5-year OS
(95% CI)
Events 5-year PFS
(95% CI)
Crude HR (95% CI) Adjusted HRa
(95% CI)
Overall 639 34 94.6 (92.1–96.4) 179 69.4 (65.3–73.1)
Sex P ¼ .734 P ¼ .277 P ¼ .277 P ¼ .434
Female 326 19 94.0 (89.9–96.5) 98 67.6 (61.6–72.9) 1.00 1.00
Male 313 15 95.2 (91.6–97.3) 81 71.1 (65.3–76.2) 0.85 (0.63–1.14) 0.88 (0.63–1.22)
Age in 5 groups P, .001 P, .001 P, .001 P ¼ .015
.10 187 9 95.4 (90.5–97.8) 36 77.2 (69.6–83.1) 1.00 1.00
5–10 213 10 95.4 (90.8–97.8) 42 79.1 (72.4–84.3) 0.98 (0.63–1.53) 0.94 (0.59–1.49)
3–5 110 3 97.4 (89.5–99.4) 44 58.4 (47.7–67.7) 2.22 (1.43–3.45) 1.87 (1.14–3.09)
1–3 101 3 95.3 (86.1–98.5) 40 55.7 (44.6–65.4) 2.10 (1.34–3.30) 1.62 (0.97–2.70)
,1 28 9 75.6 (53.3–88.3) 17 40.9 (21.8–59.2) 4.69 (2.63–8.36) 1.82 (0.92–3.58)
NF1 status P ¼ .15 P ¼ .20 P ¼ .205 P ¼ .192
NF1 (2) 534 32 94.1 (91.1–96.1) 154 68.8 (64.3–72.9) 1.00 1.00
NF1 (+) 101 2 97.6 (90.7–99.4) 24 72.2 (61.0–80.7) 0.76 (0.49–1.16) 0.65 (0.34–1.24)
Pathology review P, .001 P, .001 P ¼ .002 P ¼ .008
Pilocytic astrocytoma 407 13 97.3 (94.6–98.7) 111 71.5 (66.5–75.9) 1.00 1.00
Fibrillary astrocytoma 38 9 76.5 (58.3–87.6) 19 42.6 (24.7–59.3) 2.37 (1.45–3.85) 1.99 (1.11–3.58)
Clinical diagnosis 135 4 97.4 (92.1–99.2) 33 72.3 (62.5–80.0) 0.88 (0.59–1.29) 0.28 (0.11–0.74)
Other eligible typesb 32 6 69.1 (38.1–86.8) 10 55.6 (20.4–80.5) 1.94 (1.01–3.71) 1.22 (0.60–2.48)
Mixed neuronal-glial
tumors
27 2 83.3 (40.7–96.4) 6 69.6 (43.4–85.4) 0.92 (0.40–2.09) 0.74 (0.31–1.78)
Site review P, .001 P, .001 P, .001 P ¼ .474
Cerebellum 202 2 98.4 (93.6–99.6) 27 85.4 (79.4–89.8) 1.00 1.00
Cerebral hemisphere 102 7 89.0 (73.4–95.7) 20 74.1 (61.6–83.1) 1.87 (1.05–3.34) 1.21 (0.63–2.34)
Optic nerve only 38 0 100.0 5 86.1 (69.7–94.0) 0.98 (0.38–2.54) 0.61 (0.16–2.28)
Chiasma/
hypothalamus
157 12 94.4 (88.5–97.4) 72 50.2 (41.0–58.7) 4.43 (2.84–6.90) 1.74 (0.92–3.31)
Other supratentorial
midline
39 3 91.7 (76.2–97.2) 19 48.9 (32.0–63.9) 5.32 (2.95–9.57) 1.64 (0.80–3.34)
Brain stem 63 8 84.8 (71.1–92.3) 22 63.7 (49.8–74.7) 3.22 (1.83–5.65) 1.23 (0.65–2.33)
Spinal 29 0 100.0 10 62.3 (41.1–77.8) 3.39 (1.64–7.00) 0.99 (0.45–2.16)
Extent of tumor
resection
P, .001 P, .001 P, .001 P, .001
Total 205 1 98.9 (92.3–99.8) 38 94.0 (89.0–96.7) 1.00 1.00
Nearly total 105 1 98.9 (92.7–99.9) 54 65.6 (55.0–74.2) 8.23 (4.07–16.61) 8.19 (3.97–16.91)
Partial 87 10 90.0 (78.7–95.4) 42 48.6 (37.1–59.2) 14.11 (7.07–28.13) 12.27 (5.58–26.99)
Biopsy 103 17 83.3 (73.5–89.7) 35 41.4 (30.1–52.3) 14.96 (7.61–29.40) 11.38 (4.99–25.97)
No surgery 134 5 97.2 (91.4–99.1) 10 68.9 (59.2–76.7) 6.48 (3.23–13.01) 19.79 (6.11–64.14)
Metastasis within CNS P ¼ .003 P ¼ .005 P ¼ .006 P ¼ .107
No 583 29 94.6 (91.9–96.5) 160 69.5 (33.0–74.8) 1.00 1.00
Yes 22 4 85.5 (61.4–95.1) 11 56.7 (65.1–73.4) 2.36 (1.28–4.35) 1.74 (0.89–3.41)
Abbreviations: OS, overall survival; PFS, progression-free survival; HR, hazard ratio; CI, confidence interval; NF1, neurofibromatosis type 1;
CNS, central nervous system.
aAdjusted for sex, age (in 5 groups), NF1 status, pathology (in 5 groups), site review (in 8 groups, results for ‘others’ [n ¼ 9] not shown),
extent of tumor resection, treatment decision after diagnosis (data not shown), and metastasis within CNS.
bOther eligible types: other astrocytoma (n ¼ 23) and pilomyxoid astrocytoma (n ¼ 9).
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confounding effects of multiple clinical interventions
commonly used after tumor progression. The compari-
son of OS and PFS in selected categories permits propo-
sals to be made for consideration in stratification in
future trials. The prognostic analyses were based on
HR within a multivariate analysis. The duration of
follow-up was the only criterion not entirely met, the
median follow-up time being 4.7 years against the rec-
ommendation of 5 years.
Expert central pathology review was the main method
for exclusion of ineligible cases. The large number of
patients and the small proportion of unclassifiable tumors
make this cohort unique compared with others. Eighty
percent of biopsied tumors were PA, which is a larger pro-
portion than in other reports.8,13,27–29 This difference may
have been due to the enhanced use of the diagnosis “non-
specific astrocytoma” in registry reports,26 or referral bias
within institutional reports. There were 39 (5.9%) cases
of diffuse astrocytoma corresponding to the grade II
LGG. At the time this histopathological classification was
carried out, there were no known genetic abnormalities
to assist with further biological subclassification. The
subsequent identification of copy number gains at 7q34
in PAs and grade II LGG tumors,30–34 tandemduplications
involving BRAF fusion genes KIAA1549-BRAF and
SRGAP3-RAF1,31,32,34,35 and the latter fusion genes’
capacity to give rise to anchorage-independent growth of
NiH-3T3 cells32,35 have highlighted a new method for
exploring the biology of these tumors in addition to histo-
pathological classification.
PMA is a relatively new histopathological entity that
has been proposed as an independent adverse category
for prognosis.36 We applied strict criteria for the diagno-
sis of this entity, making the diagnosis only when there
were no elements within the tumor that might suggest
a diagnosis of PA with myxoid foci. PMA and PA are
closely related. This LGG1 study has revealed a histo-
pathological overlap, and there is now an established lit-
erature on the cases of PMA that have “recurred” as
PAs.37 In addition, it is clear that some PMAs have the
characteristic BRAF/KIAA1549 fusion gene of PAs.34
It is our view that the prevalence of PMA has previously
been overestimated and that if it is to be a useful
diagnostic category, then histopathological evaluation
has to be stringent. Our results are consistent with the
poor prognosis of PMA found by others; however, this
does not reach statistical significance in the multivariate
analysis.
The clinical diagnosis of LGG without biopsy was
accepted with typical imaging in cases predominantly
associated with NF1, and by so doing, it is assumed
that their biological characteristics are comparable to
those seen in typical PAs. The survival curve pattern
and PFS rates are comparable to those of biopsy-proven
PAs, supporting the explanation and the adoption of
these selection criteria for future trials. NF1 status has
been reported as a favorable prognostic factor in
OPG.6,9,18 This study confirms this at the chiasma/
hypothalamus location, although little difference could
be shown at other sites.
The anatomical reclassification conducted in this
study left very few cases unclassified. The childhood
focus in patient recruitment means that the processes of
brain growth and development are integral to the analy-
sis. Age is proposed as a proxy for staging brain develop-
ment, which from this analysis suggests an interaction
between tumor behavior and different anatomical sites.
There was a bimodal age distribution for the whole
cohort. In the cerebellar group, none presented clinically
under the age of 1 year. The chiasmatic/hypothalamic
group shows an early peak (4 years of age) and a declining
incidence in subsequent age groups, whereas the cerebral
cortex tumors show a rising incidence with age. These
different age-incidence patterns are intriguing, suggesting
that they may be a product of time taken for tumors to
reach a critical size for symptomatic presentation.
Alternatively, that they could be an expression of the
microenvironment at different sites and ages promoting
differential rates of tumor development and growth.38
This latter view, in our opinion, appears compatible
with the very large, predominantly chiasmatic/hypo-
thalamic tumors presenting under 1 year and the overall
impact of early age (,5 years) on the risk for tumor pro-
gression in the univariate and multivariate analyses.
In this study, age ,1 year was predictive of poorer OS,
with 84.7% and 75.6% 3- and 5-year OS, respectively,
Fig. 4. The Kaplan–Meier curves of OS. (A) OS, all; (B) OS by age group.
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compared with 95.3%–100% 3-year OS and 95.3%–
97.4% 5-year OS in the other age groups. This difference
in OS between ,1 year and other age groups in our study
was statistically significant (P, .001). Many smaller
studies on LGG in children have looked at age as a prog-
nostic factor for OS, with inconsistent results. In the
largest study, with 278 patients, there was no difference
in OS between children ,5 and .5 years.13 The obser-
vation of a significant difference for children ,1 year in
this, the largest population-based study published to
date, is in contrast to the previously published smaller
and institution-based studies, the majority of which were
restricted to OPG. The published meta-analysis of OPG
concluded that age ,1 year is an independent prognostic
factor for survival at this site.26
PFS in this analysis showed a significant correlation
with the age groups. Other published studies including
LGG at all sites show young age (,2 or ,5 years)
being a negative prognostic factor for PFS,8,17 whereas
others could not verify this13,15 or even found young
age a positive prognostic factor for PFS.14 Two studies
that showed a significantly worse PFS in children ,1
year compared with 1–5 and 5–10 years were stratified
to recruit children for the trial of chemotherapy, in order
to delay radiotherapy and its attendant neurotoxicity, in
very young children.18,19 This stratified design precludes
full interpretation of the independent impact of age on
outcome in these studies. The study by the Gesellschaft
fur Paediatrische Onkologie und Haematologie
(GPOH) identified age .10 years as a poor prognostic
factor for PFS.19 This is in contrast to our observation
regarding the impact of age upon progression. One
explanation may be that the GPOH study is also report-
ing a trial of chemotherapy, which may have selected
older children with more resistant tumors requiring
treatment at late stage. The same explanation may be
applied to the study identifying age .5 years as a cat-
egory with a worse PFS than ,5 years.14 Studies of
OPG with other age cutoffs found young age either to
be a negative factor9,11,12 for PFS or to have no
influence.6
We have observed a marked discrepancy between PFS
and OS rates overall, and a particular discrepancy for the
impact of different age categories upon these 2 outcome
parameters. This discrepancy underlines the chronic
nature of the clinical course for patients with these
tumors, which threaten life infrequently, yet continue
to be at a sustained risk for progression when unresect-
able. The discrepancy between age groups with respect
to OS versus PFS would support the hypothesis we set
out to test, that age is a factor determining the risk for
tumor progression; this seems particularly applicable
in hypothalamic/chiasmatic tumors in the ,1- and 1–
5-year age groups. Previously published studies report-
ing both endpoints showed similar impact of age (with
cutoff at age 2, 3, or 5 years) for PFS and OS,8,12,17
although this was not commented upon. In contrast,
we consider this observation of the discrepant impact
of age upon PFS and OS as important, justifying the pro-
posal that age should be a major factor for stratification
of future trials.
We note that the adjusted HRs remained significant
or borderline significant in younger age groups,
suggesting that the effect is probably independent of
treatment groups. This is a challenging conclusion
from this analysis. In this study, after registration and
surgery, 474 (74.2%) patients were initially observed,
of whom 108 (16.9%) subsequently progressed. One
hundred and sixty-five patients (25.8%) received initial
nonsurgical therapy at diagnosis: 113 (17.6%) received
chemotherapy and 52 (8.1%) received radiotherapy;
58 (9.1%) and 12 (1.9%), respectively, progressed.
The selection of these nonsurgical treatments was deter-
mined by age at diagnosis within the treatment strategy.
The majority of first progressions (16.9%) occurred in
patients after primary observation, compared with
11.1% after primary nonsurgical treatment and having
done the analysis with and without treatment effects
and presented the model with the inclusion of treatment
decisions. We conclude that although there is an inter-
action between age and nonsurgical treatment, the
greater proportion of progressions occurring after obser-
vation lends greater weight to age rather than treatment
as a cause of progression, especially as treatment was
given with the intention of delaying progression.
Optic pathway tumors constitute an important clini-
cal group within LGGs, as their presentation is associ-
ated with a clinical concern about vision loss.
Treatment is commonly initiated in order to “save
vision.” The anatomical classification conducted here
permitted differentiation between isolated optic nerve
and chiasmatic OPG. This anatomical separation was
associated with marked differences in PFS at these sites
within the optic tract (Fig. 3G), optic nerve tumors pro-
gressing very infrequently. A recent description of a
more detailed anatomical and genetic classification of
OPGs offers a new way to study the impact of therapy
on the risk for vision loss and anatomical and genetic
factors that may influence long-term visual outcomes.39
Most studies find PA a favorable prognostic
factor,7,10,13,17 but others not.8,14 In this study, FA was
an independent adverse risk factor for both PFS and OS,
compared with PA. This effect was greater for OS than
PFS, an observation not commented upon, yet recorded
in previous studies.7,17 This difference between OS and
PFS rates emphasizes the sustained tendency of PA to pro-
gress compared with a more classical tumor paradigm for
FA, where progression is more strongly linked to survival.
In conclusion, this is the largest population-based
study of LGG in childhood published to date. It has
identified significant interactions between age at presen-
tation and anatomical site as well as anatomical site and
resectability. It has identified age at diagnosis, histologi-
cal grade, extent of surgical resection, and hypothala-
mic/chiasmatic location as significant predictors for
tumor progression. It has emphasized the sustained
risk for tumor progression in chiasmatic/hypothalamic
tumors. Clinically, these factors underline the impor-
tance of surgical resection for control of tumor pro-
gression and will be used to stratify future clinical
trials of new and hopefully more effective nonsurgical
therapies. These observations support hypotheses being
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tested in the current biological research in this
field.32,34,40,41 We propose the hypothesis that the risk
for tumor progression at the hypothalamic/chiasmatic
location diminishes with age and is a product of an inter-
action between tumor factors (genetic) and the ontogeny
of factors determining characteristics of human brain
growth and development within the hypothalamic/
chiasmatic region.
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